Mineralys Therapeutics (MLYS) Return on Assets (2023 - 2026)

Quarterly results put Return on Assets at 0.0% for Q1 2026, changed 0.0% from a year ago — trailing twelve months through Mar 2026 was 0.0% (changed 0.0% YoY), and the annual figure for FY2025 was 0.0%, changed 0.0%.

Mineralys Therapeutics has reported Return on Assets over the past 4 years, most recently at 0.0% for Q1 2026.

  • Return on Assets reached 0.0% in Q1 2026 per MLYS's latest filing, up from 0.0% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.0% in Q2 2023 and bottomed at 0.01% in Q4 2024.
  • Median Return on Assets over the past 4 years was 0.0% (2024), compared with a mean of 0.0%.
  • The largest annual shift saw Return on Assets changed 0bps in 2024 before it grew 1bps in 2025.
  • Over 4 years, Return on Assets stood at 0.0% in 2023, then tumbled by -176bps to 0.01% in 2024, then surged by 67bps to 0.0% in 2025, then rose by 6bps to 0.0% in 2026.
  • Business Quant data shows Return on Assets for MLYS at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROA (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -0.01%
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn 0.00%
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -0.01%
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 0.00%
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 0.00%
8 Evaxion A 65.12 Bn 65.10 Bn - 0.00%
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 0.00%
10 Mineralys Therapeutics 2.50 Bn 2.50 Bn - 0.00%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 0.00%
Dec 31, 2025 0.00%
Sep 30, 2025 0.00%
Jun 30, 2025 -0.01%
Mar 31, 2025 -0.01%
Dec 31, 2024 -0.01%
Sep 30, 2024 -0.01%
Jun 30, 2024 0.00%
Mar 31, 2024 0.00%
Dec 31, 2023 0.00%
Sep 30, 2023 0.00%
Jun 30, 2023 0.00%
Mar 31, 2023 0.00%